This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.
Following two years of using Ocrevus twice-yearly, 75% of relapsing-remitting multiple sclerosis (RRMS) patients had no evidence of disease activity. ... Ocrevus. Patients treated with Ocrevus also experienced an improvement in the majority of their
However, the drug will have fierce competition in the market, from rivals such as Roche’s Ocrevus (ocrelizumab) and Sanofi’s Aubagio, despite touting superior efficacy data over the latter. ... Both Kesimpta and Ocrevus selectively target the immune
The FDA approval of Enspryng, the first subcutaneous NMOSD treatment using novel recycling antibody technology, builds upon the work we’ve done in multiple sclerosis with Ocrevus to develop
The MS market has long been dominated by Roche’s blockbuster drug Ocrevus (ocrelizumab), which is used in both relapsing forms of MS and primary progressive MS, although it is facing
Although sales of Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to ... In fact, uptake of both
A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).
More from news
Approximately 20 fully matching, plus 35 partially matching documents found.
To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...